Invitrogen™ CD20 Monoclonal Antibody (AISB12), Functional Grade, eBioscience™, Invitrogen™

Description

Description: The AISB12 monoclonal antibody reacts with mouse CD20. CD20 is a B cell-specific 32kDa membrane protein involved in intracellular calcium regulation. CD20 expression begins after the induction of CD19 during development, and is coexpressed with IgM during the pre-B to immature B cell transition in bone marrow. Expression then increases during maturation with almost all mature cells expressing some level of CD20. The human CD20 antigen has proven to be an effective immunotherapeutic target in B cell lymphoma and several autoimmune diseases including rheumatoid arthritis and type I diabetes. CD20 consists of 4 transmembrane domains and a 44 amino acid extracellular loop domain where AISB12 binds. Applications Reported: This AISB12 antibody has been reported for use in flow cytometric analysis, western blotting and functional assays. Applications Tested: This AISB12 antibody has been tested by flow cytometric analysis of mouse splenocytes. This can be used at less than or equal to 0.25 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Endotoxin: Less than 0.001 ng/ug antibody as determined by the LAL assay. Storage and handling: Use in a sterile environment.

CD20 is a non-glycosylated surface phosphoprotein that has a molecular weight range of 33-37 kDa depending on the degree of phosphorylation. CD20 is expressed on mature and most malignant B cells, in a subpopulation of T lymphocytes and follicular dendritic cells. CD20 expression on B cells is synchronous with the expression of surface IgM and it regulates transmembrane calcium conductance, cell cycle progression and B-cell proliferation. CD20 is also associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change, and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following monoclonal antibody treatment. Diseases associated with CD20 dysfunction include Ms4a1-related common variable immune deficiency.